TIDMPBX
RNS Number : 6567G
Probiotix Health PLC
31 March 2022
ProBiotix Health plc
("ProBiotix Health" or the "Company")
Admission to trading on AQSE and first day of dealings
ProBiotix Health plc (AQSE: PBX), a life sciences business
developing probiotics to tackle cardiovascular disease and other
lifestyle conditions, announces that 121,666,666 ordinary shares of
0.05p each in the Company ("Ordinary Shares") are today being
admitted to trading on the Access Segment of the AQSE Growth Market
("Admission").
In connection with Admission, ProBiotix Health has raised GBP2.5
million through a placing and subscription of 11,904,762 Ordinary
Shares at a price of 21p per share.
The Directors of ProBiotix Health believe that an investment in
the Company represents an opportunity to invest in an innovative
technology that is underpinned by a significant portfolio of
Intellectual Property Rights, supported by an experienced board,
and applicable to a range of markets.
Key information:
-- ProBiotix Health is the holding company of ProBiotix Limited ("ProBiotix").
-- ProBiotix was established by AIM-listed OptiBiotix Health plc
("OptiBiotix"), a global leader in microbiome modulating compounds
for use in functional foods and supplements, to develop probiotics
to tackle cardiovascular disease and other lifestyle
conditions.
-- The Company's strategy is to develop next-generation
microbiome solutions for a wide range of health conditions and to
deliver commercially successful products supported by a strong
scientific evidence base.
-- Since its creation, ProBiotix has made considerable progress
and has successfully transitioned from a research and development
specialist into a profitable commercial organisation whose products
are being commercialised in over 60 countries.
-- Human volunteer studies have shown that ProBiotix's principal
product, Lactobacillus plantarum ECGC13110402 ("LP-LDL(R)"), can
reduce key cardiovascular risk markers, such as total cholesterol,
LDL (bad) cholesterol, and Apolipo protein B, by up to 34.2 per
cent, 28.4 per cent and 28.6 per cent respectively.
-- ProBiotix commercialises LP-LDL(R) as an ingredient and in a
range of white and own label products under its CholBiome(R)
range.
-- The CholBiome(R) portfolio currently comprises four products,
which can either be sold under the CholBiome(R) brand or private
label:
-- CholBiome (R)
Contains LP-LDL(R) as the only active ingredient, to focus on
healthy cholesterol maintenance and deliver tangible health
benefits.
-- CholBiome (R)(X3)
A cholesterol-reducing formula that combines three targeted
ingredients into a triple-layer tablet. It consists of LP-LDL(R),
Monacolin K from red yeast rice, and Vitamin B3 (niacin) to deliver
a tri-factor approach that utilises synergistic mechanisms of
action to reduce cholesterol and aid overall cardiovascular
health.
-- CholBiome (R)(BP)
A blood pressure reducing formula that combines four
science-backed natural ingredients, LP-LDL(R) Thiamine (Vitamin
B1), L-arginine and CoEnzyme Q10, to provide a multi-targeted
mechanism approach for aiding hypertension and improving
cardiovascular health.
-- CholBiome(R)(VH)
A vascular health formula that combines three specialised
ingredients in a triple layer tablet. Consisting of LP-LDL(R)
Thiamine and Vitamin K2 Vital (from Kappa Bioscience) to provide a
multi-targeted mechanism to work against the build-up of lipid and
calcium deposits in the blood vessels.
-- In February 2019, LP-LDL(R) was designated Generally
Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in
the United States, which extends its applications from use as a
supplement to use as a functional ingredient in a wide range of
food, dairy, and beverage products in the USA.
-- ProBiotix currently has 27 registered patents to its name and
will continue to expand its IP portfolio as it expands its
application areas and territories.
-- On 28 February 2022, OptiBiotix announced that preliminary
unaudited results for ProBiotix for the year ended 31 December
2021, indicated total sales of GBP1.1 million.
-- Following a distribution in specie of Ordinary Shares to its
shareholders, OptiBiotix remains interested in 53,533,333 Ordinary
Shares, representing approximately 44% of the Company's issued
share capital.
Peterhouse Capital Limited is acting as the Aquis Stock Exchange
Corporate Adviser and Broker.
Stephen O'Hara, CEO of Probiotix Health plc commented : " We are
very pleased with the level of interest generated from new
investors in support of our admission to trading on AQSE. This IPO
represents a landmark moment for Probiotix as an independent
company in its own right and will enable our business to continue
to grow as we expand our territories and product range into dairy
and pharma.
"T he global probiotics market was estimated to be valued at USD
61.1 billion in 2021 and is projected to reach USD 91.1 billion by
2026. The growth is expected to be driven by the increasing
consumer inclination towards preventive healthcare in conjunction
with the development of safe and effective probiotic strains and we
are well placed to take advantage of this."
Directors and Key Management
The Directors of the Company are as follows:
Adam Reynolds - Non-executive Chairman (aged 59)
Adam began his career in the City in 1980 and in 2000
established his own PR/IR/Corporate finance firm which listed on
AIM in November 2000 and was then later sold in 2004 via a reverse
takeover.
He was approached in 2005 to become non-executive Chairman of
International Brand Licensing Plc ("IBL"). The company at this time
had substantial debt and the remit was to turn it around. Following
the sale of a number of global sports IP assets, IBL became a cash
shell. In 2009 Adam introduced David Evans and Julian Baines, two
leading diagnostic specialists in the UK, to the company and the
Plc changed direction. That business is today called EKF Diagnostic
Holdings Plc, and Adam remains a non-executive director and
shareholder.
In November 2012, Adam launched a successful agreed bid for the
trading assets and business of Autoclenz Plc alongside its
management team. Adam remains a director and shareholder.
In addition, Adam is currently non-executive Chairman of
AIM-quoted Belluscura plc, Yourgene Health Plc and MyHealthChecked
Plc, and a non-executive director of Sosandar Plc.
Stephen O'Hara - Chief Executive Officer (aged 61)
Stephen trained as a microbiologist and has over 50
publications, 70 plus patents, and chapters in a number of books.
Whilst a scientist by training, Stephen is at heart an entrepreneur
with a track record of success in identifying opportunities,
raising finance, commercialising products and taking companies to
exit by IPO or trade sale. Stephen has built several businesses and
was a founder of Acolyte Biomedica which he exited to 3M Healthcare
in 2007 (at a 32x multiple) whereupon he became Director of
Healthcare at 3M.
Stephen has been a director of an investment company and is
frequently asked to advise on potential investments by
institutional investors.
Stephen founded OptiBiotix in May 2012, SkinBiotherapeutics plc
in 2015 (initially as a joint venture with the University of
Manchester) and ProBiotix in 2018, to commercialise opportunities
in the immature but evolving microbiome field. Stephen listed
OptiBiotix on AIM in August 2014 and SkinBiotherapeutics plc in
April 2017.
Mikkel Hvid-Hansen - Commercial Director (aged 53)
Prior to joining ProBiotix, Mikkel was International Sales
Manager for Cell Biotech Int., a Korean probiotic company selling
bulk ingredients and finished products internationally.
Mikkel previously spent six years as International Sales Manager
at Bifodan, where he had responsibility for the sales of several
probiotic OTC drugs. Previously, Mikkel also worked for Lallemand,
the world's third largest probiotic company (1998-2006) and Eraco
(1995-1998). Mikkel has extensive experience of commercialising
probiotics products and technologies, a wide network of industry
contacts, and a strong track record of rapidly growing sales.
Marco Caspani - Independent Non-executive Director (aged 47)
Marco has been working in the health ingredients industry for
more than 18 years. With a degree in food science, Marco has an
international network of connections with Industry leaders. Marco
joined CSL in 2012, who are recognised as global leaders in the
development and production of strains for the food and
pharmaceutical Industries.
Key Management
The Company's finance function will be the responsibility of
Mark Collingbourne, who is currently the Chief Finance Officer at
OptiBiotix.
Mark Collingbourne - Chief Finance Officer
Mark is a qualified accountant with significant experience in
financial management, particularly in the area of publicly quoted
companies. He is currently Chief Finance Officer at OptiBiotix and
Intuitive Investments Group plc. He has dealt with all aspects of
PLC development from bringing small companies to flotation to
supervising the on-going accountancy and ensuring the good
governance of international businesses. During his ten-year tenure
with ViaLogy plc (now Yourgene Health plc), Mark was a key member
of the team that arranged its transformation from a private US
organisation to an AIM company, via a merger with Original
Investments PLC. He also played a major part in arranging the
financial details of ViaLogy's restructuring. Previously, after
periods with ITV Network Centre and Mechanical Copyright Protection
Society Limited, Mark was appointed Finance Director of Curtis
Brown Group Limited, one of the UK's leading literary agencies, in
1996, where he managed the financial implications of the management
buyout in 2001.
Total Voting Rights
For the purposes of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules, ProBiotix Health has 121,666,666
Ordinary Shares in issue. This figure of 121,666,666 Ordinary
Shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Probiotix Health plc Contact via Walbrook below
Stephen O'Hara, Chief Executive
Peterhouse Capital Limited Tel: 020 7469 0930
Mark Anwyl (AQSE Corporate Adviser)
Duncan Vasey (Broker)
Walbrook PR Ltd Mob: 07876 741 001 or probiotix@walbrookpr.com
Anna Dunphy
About ProBiotix Health plc
ProBiotix Health develops probiotics (live microbes that, when
ingested, can alter the composition of the microbiome and improve
human health) to tackle cardiovascular disease and other lifestyle
conditions which are affecting growing numbers of people across the
world.
ProBiotix Health's cholesterol reducing probiotic, Lactobacillus
plantarum ECGC13110402 ("LP-LDL(R)), is manufactured in
pharmaceutical GMP-certified facilities and protected worldwide by
in the region of 5 patent families, comprising 27 patents and
pending patent applications, and 22 trademarks.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDZGFFKGRGZZM
(END) Dow Jones Newswires
March 31, 2022 02:01 ET (06:01 GMT)
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Oct 2023 to Oct 2024